Skip to content

Comparision of Dexmedetomidine and Dexamethasone With levobupivacaine in transverse abdominies plane block for postoperative pain relief in patient undergoing total abdominal hystrectomies

Dexmedetomidine verses Dexamethasone As adjuvant to levobupivacaine in usg guided transverse abdominies plane block for postop analgesia in patient undergoing total abdominal hystrectomies

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030607
Enrollment
72
Registered
2021-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O9A1- Malignant neoplasm complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: USG guided TAP block: USG guided TAP block given after total abdominal hysterectomy under SAB for post op analgesia Control Intervention1: Group A patient will receive TAP BLOCK with DE
USG guided TAP block will be given with the anesthetic solution mixture consisted of a total volume of 40 ml levobupivacaine 0.25 % and dexamethasone 8 mg, 20 ml injected on each side. Control Interve

Sponsors

Department of Anaesthesia Himalayan Institute of Medical Science
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: American society of anesthesiologists (ASA) physical status grade 1 and 2. Age of 18 years and more. Patients who will be scheduled for total abdominal hysterectomies.

Exclusion criteria

Exclusion criteria: Patient refusal. Body mass index (BMI) > 40. Patients with chronic pain and those using chronic analgesic medications. Coagulopathy. Allergy to the study drugs. Patients taking other medications with Ã?±-adrenergic blocking effect. Hepatic insufficiency (Liver enzymes elevated more than 2 times of normal values) Renal insufficiency ( Serum Creatinine elevated more than 2 times of normal values) Systemic infection. Infection at the site of injection. Ã?Â

Design outcomes

Primary

MeasureTime frame
Duration and quality of analgesia 2- Post operative analgesic consumption Ã? Timepoint: Duration and quality of analgesia 2- Post operative analgesic consumption Ã?Â

Secondary

MeasureTime frame
Adverse effect or complication if anyTimepoint: postoperatively at 20,1,3,6,9,12,18,23

Countries

India

Contacts

Public ContactDrVeena Asthana

Himalayan institute of medical sciences

jyoti18sinha@gmail.com9599020524

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026